Colossal Biosciences in talks to raise at $20B–$30B valuation
Original: Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
Why This Matters
Valuation doubling signals surging investor appetite for deep-tech biotech and de-extinction platforms.
De-extinction startup Colossal Biosciences is reportedly in talks to raise new capital at a $20B–$30B valuation, up from its prior $10.2B valuation roughly 16 months ago, according to Axios. The five-year-old company has begun generating revenue over the past year.
De-extinction startup Colossal Biosciences is in talks to raise new funding at a valuation of $20 billion to $30 billion, Axios reported on July 20, 2026. This marks a significant jump from the company's previous $10.2 billion valuation, which was established approximately 16 months ago when it announced efforts to 'resurrect' the dire wolf using genetic material from fossils. The round's lead investor and exact capital target have not been disclosed. According to the report, Colossal has begun generating revenue over the past year. CEO and co-founder Ben Lamm previously outlined three revenue streams: conservation technology licensing (including contracts with the U.S. government and the UAE, which invested $60 million), spinout companies, and potential future biodiversity credit sales if extinct species are reintroduced to habitats. Colossal has spun out three companies: Breaking (plastic degradation), Form Bio (computational biology, $30M raised), and Astromech (AI-driven biological modeling, valued at $2B in March 2026). Lamm also noted plans to spin off artificial animal womb technology, which he told Rolling Stone in May could be ready by next year. Colossal did not respond to TechCrunch's request for comment.